Market research
URGN UroGen Pharma Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 60
- Dividend yield
- Not available
- Beta
- 1.57
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011407140
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 60
- Dividend yield
- Not available
- Beta
- 1.57
About
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the URGN discussion.
5 years, 4 months ago
UroGen Pharma Ltd is currently in a long term downtrend where the price is trading 25.1% below its 200 day moving average.
From a valuation standpoint, the stock is 97.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 35.8.
UroGen Pharma Ltd's total revenue rose by inf% to $8M since the same quarter in the previous year.
Its net income has increased by 21.7% to $-31M since the same quarter in the previous year.
Finally, its free cash flow grew by 18.2% to $-21M since the same quarter in the previous year.
Based on the above factors, UroGen Pharma Ltd gets an overall score of 4/5.